The rise of theranostics: Part 4 -- Women's theranostics on the horizon
AuntMinnie
JULY 8, 2024
Several presenters at the Society for Nuclear Medicine and Molecular Imaging's (SNMMI) 2024 meeting in Toronto shared new findings in women's studies. CAM-H2-I-131 is specific, reaches HER2 positive lesions, and is retained in lesions for at least seven days, according to research presented by Precirix during SNMMI 2024.
106 
Let's personalize your content